RISK OF SYSTEMIC METASTASES IN CLINICAL STAGE I NONSEMINOMA GERM CELL TESTIS TUMOR MANAGED BY RETROPERITONEAL LYMPH NODE DISSECTION

This publication has 25 references indexed in Scilit:

• Clinical stage B non-seminomatous germ cell testis cancer: The Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection
  European Journal Of Cancer, 1995
• Flow‐cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical‐stage‐I non‐seminomatous testicular germ‐cell tumors
  International Journal of Cancer, 1994
• Primary Retroperitoneal Lymph Node Dissection in Clinical Stage A Non‐seminomatous Germ Cell Testis Cancer Review of the Indiana University Experience 1965–1989
  British Journal of Urology, 1993
• Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols
  JNCI Journal of the National Cancer Institute, 1993
• Pilot Study to Evaluate Impact of a Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer Patients
  Journal of Urology, 1992
• Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.
  Journal of Clinical Oncology, 1992
• Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
  The Lancet, 1991
• Identifying patients with low risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance
  Urology, 1989
• HISTOPATHOLOGY IN THE PREDICTION OF RELAPSE OF PATIENTS WITH STAGE I TESTICULAR TERATOMA TREATED BY ORCHIDECTOMY ALONE
  The Lancet, 1987
• Chemotherapy in Non-seminomatous Testicular Tumours Stage I
  British Journal of Urology, 1981